Results 191 to 200 of about 54,010 (241)
Relative Clinical Efficacy and Safety of Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer: A Rapid Review and Network Meta-Analysis. [PDF]
J Gastrointest CancerSharma S +7 more
europepmc +1 more source
Defying the Odds in Recurrent Glioblastoma: Complete Response following Salvage Therapy with Bevacizumab and Irinotecan - A Case Report. [PDF]
Case Rep OncolYousefi A, Saraee E, Ghalehtaki R.
europepmc +1 more source
Inflammation-tumor burden interaction score stratifies survival after irinotecan-eluting bead chemoembolization for colorectal liver metastases. [PDF]
Front Med (Lausanne)Doğan T +11 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs of Today, 1998
Irinotecan (CPT-11) is a semisynthetic derivative of camptothecin, an alkaloid extracted from the Chinese plant Camptotheca acuminata. It bears a bis-piperidine moiety and was selected for its water solubility and promising preclinical antitumor activity in in vitro and in vivo models. The target of drugs of the camptothecin family is DNA topoisomerase
J, Robert, L, Rivory
openaire +2 more sources
Irinotecan (CPT-11) is a semisynthetic derivative of camptothecin, an alkaloid extracted from the Chinese plant Camptotheca acuminata. It bears a bis-piperidine moiety and was selected for its water solubility and promising preclinical antitumor activity in in vitro and in vivo models. The target of drugs of the camptothecin family is DNA topoisomerase
J, Robert, L, Rivory
openaire +2 more sources
Pharmacogenetics of Irinotecan
Current Medicinal Chemistry-Anti-Cancer Agents, 2003Pharmacogenetics focuses on intersubjects variation in therapeutic drug effects and toxicity depending on genetic polymorphisms. This is particularly interesting in oncology since anticancer drugs usually have a narrow margin of safety. Irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin] is used in cancer chemotherapy as a ...
G, Toffoli +3 more
openaire +2 more sources
Current Opinion in Supportive & Palliative Care, 2007
The toxicity of irinotecan is predictable, manageable and nonadditive in the majority of patients; however, with its increasing use alone and in combination with other agents and modalities, the recognition and control of these adverse effects remain a clinical challenge.
openaire +2 more sources
The toxicity of irinotecan is predictable, manageable and nonadditive in the majority of patients; however, with its increasing use alone and in combination with other agents and modalities, the recognition and control of these adverse effects remain a clinical challenge.
openaire +2 more sources